Flomics participates in LUMINA, a Eurostars-funded project to detect lung cancer recurrence through liquid biopsy and artificial intelligence
Barcelona – July 8, 2025 –
Flomics Biotech is part of the international consortium led by RenovaroCube that has been selected for funding by the Eureka Eurostars programme. The project LUMINA, which started on 1st June 2025 and with a duration of 3 years, aims to develop an innovative platform for the non-invasive detection of minimal residual disease (MRD) in lung cancer patients using multi-omic biomarkers and artificial intelligence algorithms.
Minimal residual disease remains one of the most pressing challenges in oncology, particularly in lung cancer, where up to 60% of patients treated with curative intent experience relapse. LUMINA seeks to address this unmet need by analysing blood samples—through liquid biopsy—and integrating RNA and DNA circulating biomarkers with advanced predictive models. This approach will enable early identification of disease progression, even before it becomes clinically or radiologically evident, allowing for timely therapeutic decisions and improving patient outcomes.
Flomics brings its expertise in total RNA analysis for liquid biopsy applications, a field in which the company has positioned itself as a leader in recent years. Its technology enables the detection of complex molecular signatures that complement DNA-based analyses, ultimately enhancing the platform’s sensitivity and specificity. Combined with machine learning tools developed by RenovaroCube, this multi-omic approach could redefine clinical standards for post-treatment monitoring.
The consortium also includes Uppsala University, a European leader in biomedical research and biobanking, and Oncodia AB, a Swedish company specialized in the development of CE/IVD-certified molecular diagnostic products for cancer. This transnational collaboration brings together complementary expertise to cover all phases of the project—from biomarker discovery to clinical implementation.
Flomics’ activities in LUMINA are supported by a grant of 619 k€ from the CDTI, under the Ministry of Science, Innovation and Universities of Spain.
With this new milestone, Flomics strengthens its position as a key player in the development of advanced RNA-based diagnostics and reaffirms its commitment to precision medicine and international collaboration.
For media inquiries, partnership opportunities, or investment discussions, please contact:
📧 info@flomics.com
